Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kane Biotech has retained BioVectra, a biopharmaceutical firm, to manufacture clinical grade DispersinB to be used in the company's chronic wound care product.
Subscribe to our email newsletter
The company said that in addition to alomost 35 years of experience serving a global customer base, BioVectra’s FDA-approved cGMP facility was a key factor in awarding the contract.
Gord Froehlich, president and CEO of Kane Biotech, said: “We are excited to be moving DispersinB into the manufacturing process stage and working with BioVectra on this initiative. The production of clinical grade DispersinB is an integral part of our development plans to bring this technology to market.”